4-[4-(2-Iodo-5-methanesulfonyl-benzoyl)-piperazin-1-yl]-benzonitrile | 847547-25-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-[4-(2-Iodo-5-methanesulfonyl-benzoyl)-piperazin-1-yl]-benzonitrile
• 英文别名: 4-[4-(2-iodo-5-methanesulfonylbenzoyl)piperazin-1-yl]benzonitrile；4-[4-(2-iodo-5-methylsulfonylbenzoyl)piperazin-1-yl]benzonitrile
• CAS: 847547-25-5
• 化学式: C₁₉H₁₈IN₃O₃S
• 分子量: 495.341
• InChiKey: VJHKVFHVJHTSHU-UHFFFAOYSA-N

物化性质

• 沸点：
  710.1±60.0 °C(Predicted)
• 密度：
  1.72±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  89.9
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-[4-(2-Iodo-5-methanesulfonyl-benzoyl)-piperazin-1-yl]-benzonitrile 、 丙烯腈 在 bis-triphenylphosphine-palladium(II) chloride 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 2.0h， 生成 4-{4-[2-((E)-2-cyanovinyl)-5-methanesulfonylbenzoyl]piperazin-1-yl}benzonitrile
  参考文献：
  名称：

  Substituted acylpiperazine derivatives

  摘要：

  该发明涉及以下式中的化合物，其中取代基如规范中定义，并且其药用可接受的酸盐。该发明还涉及治疗精神病、疼痛、记忆和学习中的神经退行性功能障碍、精神分裂症、痴呆症以及其他认知过程受损的疾病的方法，如注意力缺陷障碍或阿尔茨海默病。

  公开号：

  US20050059668A1
• 作为产物：
  描述：

  2-iodo-5-methanesulfonyl-benzoic acid 、 4-哌嗪基苯甲腈 在 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以87%的产率得到4-[4-(2-Iodo-5-methanesulfonyl-benzoyl)-piperazin-1-yl]-benzonitrile
  参考文献：
  名称：

  Sulfanyl substituted phenyl methanones

  摘要：

  本发明涉及以下式I的化合物，其中R1、R2、R3、X、X1和n如规范中所定义，并且其药用可接受的酸盐。这些化合物是良好的甘氨酸转运蛋白1（GlyT-1）抑制剂，用于治疗中枢神经系统疾病，如精神分裂症、认知障碍和阿尔茨海默病。

  公开号：

  US20060149062A1

文献信息

• SULFANYL SUBSTITUTED PHENYL METHANONES
  申请人：Jolidon Synese

  公开号：US20080287455A1

  公开（公告）日：2008-11-20

  The present invention relates to compounds of formula I wherein R 1 , R 2 , R 3 , X, X 1 , and n are as defined in the specification and pharmaceutically acceptable acid addition salts thereof. These compounds are good inhibitors of the glycine transporter 1 (GlyT-1) for the treatment CNS disorders, such as schizophrenia, cognitive impairment, and Alzheimer's disease.

  本发明涉及一种式子为I的化合物，其中R1，R2，R3，X，X1和n如规范中定义的那样，以及其药学上可接受的酸盐。这些化合物是甘氨酸转运体1（GlyT-1）的良好抑制剂，用于治疗中枢神经系统疾病，如精神分裂症，认知障碍和阿尔茨海默病。
• 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1703909A1

  公开（公告）日：2006-09-27
• US7462617B2
  申请人：——

  公开号：US7462617B2

  公开（公告）日：2008-12-09
• [EN] 1-BENZOYL-PIPERAZINE DERIVATIVES AS GLYCINE UPTAKE INHIBITORS FOR THE TREATMENT OF PSYCHOSES<br/>[FR] DERIVES DE 1-BENZOYL-PIPERAZINE COMME INHIBITEURS DU RECAPTAGE DE LA GLYCINE POUR LE TRAITEMENT DE PSYCHOSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2005023261A1

  公开（公告）日：2005-03-17

  The invention relates to compounds of formula (I) wherein Ar is substituted aryl or unsubstituted or substituted 6-membered heteroaryl, containing one, two or three nitrogen atoms, and wherein the aryl and the heteroaryl groups may be substituted by one or more substituents selected from the group consisting of hydroxy, halogen, CN, (C1­C6)-alkyl, (C1-C6)-alkyl substituted by halogen, (C1-C6)-alkoxy, (C1-C6)-alkoxy substituted by halogen, NR7R8, C(O)R9 or SO2R10; R1 is hydrogen or (C1-C6)-alkyl; R2 is halogen, (C1-C6) -alkyl, (C2-C6) -alkenyl, wherein a hydrogen atom may be replaced by CN, C(O)-R9 or (C1-C6)-alkyl, or is (C2-C6)­alkynyl, (C1-C6)-alkyl substituted by halogen, -(CH2)n-(C3-C7)-cycloalkyl, -(CH2)n-heterocycloalkyl, -C(O)-R9, -(CH2)n-aryl or -(CH2)n-5 or -6­membered heteroaryl containing one, two or three heteroatoms, selected from the group consisting of oxygen, sulphur or nitrogen wherein aryl, cycloalkyl, heterocycloalkyl and heteroaryl are unsubstituted or substituted by one or more substituents selected from the group consisting of hydroxy, halogen, (C1-C6)-alkyl, (C1-C6)-alkyl substituted by halogen or (C1-C6) alkoxy; R3, R4 and R6 independently from each other are hydrogen, hydroxy, halogen, (C1-C6)-alkyl or (C1-C6)-alkoxy; R5 is NO2, CN, C(O)R9, SO2R10 or NR11R12 ; R7 and R8 independently from each other are hydrogen or (C1-C6)-alkyl; the other substituents are defined in the claims; and to pharmaceutically acceptable acid addition salts thereof for the treatment of psychoses, pain, neurodegenerative disfunction in memory and learning, schizophrenia, dementia and other diseases in which cognitive processes are impaired, such as attention deficit disorders or Alzheimer's disease.